Actuate Therapeutics, Inc. Operating Cash Flow
Actuate Therapeutics, Inc. (ACTU) reported Operating Cash Flow of -$9.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$4.41M.
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$5.02M.
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.74M.
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.68M.
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$19.21M.
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$21.84M.
- Actuate Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$21.63M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$9.42M 10-Q · filed 2026-08-14 | -$13.16M derived: sum of 3 quarters · filed 2026-08-14 | -$19.84M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$5.02M 10-Q · filed 2026-05-14 | -$8.75M derived: sum of 2 quarters · filed 2026-05-14 | -$15.43M derived: sum of 3 quarters · filed 2026-05-14 | -$19.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$10.41M derived: sum of 2 quarters · filed 2026-03-26 | -$14.59M derived: sum of 3 quarters · filed 2026-08-14 | -$19.21M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$6.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$10.85M derived: sum of 2 quarters · filed 2026-08-14 | -$15.47M 10-Q · filed 2025-11-13 | -$20.24M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$4.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$8.79M 10-Q · filed 2026-08-14 | -$13.56M derived: sum of 3 quarters · filed 2026-08-14 | -$22.71M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$4.62M 10-Q · filed 2026-05-14 | -$9.39M derived: sum of 2 quarters · filed 2026-05-14 | -$18.54M derived: sum of 3 quarters · filed 2026-05-14 | -$21.21M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$4.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$13.92M derived: sum of 2 quarters · filed 2026-03-26 | -$16.60M derived: sum of 3 quarters · filed 2026-03-26 | -$21.84M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$9.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$11.82M derived: sum of 2 quarters · filed 2025-11-13 | -$17.07M 10-Q · filed 2025-11-13 | -$22.58M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$7.92M 10-Q · filed 2025-08-14 | -$13.43M derived: sum of 3 quarters · filed 2025-08-14 | -$19.07M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$5.25M 10-Q · filed 2025-05-15 | -$10.76M derived: sum of 2 quarters · filed 2025-05-15 | -$16.40M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$11.15M derived: sum of 2 quarters · filed 2025-03-13 | -$21.63M 10-K · filed 2025-03-13 | |
| 2023-09-30 | -$5.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$16.11M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | -$10.48M 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |